Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08UNQ
|
||||
| Former ID |
DIB002282
|
||||
| Drug Name |
NSD-644
|
||||
| Synonyms |
Serotonin/noradrenaline/dopamine activator (pain, depression, CNS disorder), NeuroSearch
|
||||
| Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Discontinued in Phase 1 | [1] | ||
| Company |
NeuroSearch A/S
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent dopamine transporter | Target Info | Activator | [2] | |
| Sodium-dependent serotonin transporter | Target Info | Activator | [2] | ||
| Sodium-dependent noradrenaline transporter | Target Info | Activator | [3] | ||
| KEGG Pathway | Dopaminergic synapse | ||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Alcoholismhsa04726:Serotonergic synapse | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter ActivityWP727:Monoamine Transport | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571) | ||||
| REF 2 | NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. | ||||
| REF 3 | Clinical pipeline report, company report or official report of Neurosearch. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.